Related Experiment Video
Updated: Feb 28, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells
Behnaz Dolatabadi1, Maryam Peymani2, Mehrdad Hashemi3,4
1Department of Biology, ShK.C., Islamic Azad University, Shahrekord, Iran.
Background:
Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in HER2-positive breast cancer (BC). Here, we identified prognostic genes modulated by lapatinib and evaluated whether glucose-functionalized, lapatinib-conjugated silver nanoparticles could enhance its anticancer efficacy.
Methods:
Lapatinib-responsive genes were identified from the GSE38376 dataset and their prognostic associations were assessed using The Cancer Genome Atlas (TCGA). Silver nanoparticles were synthesized by Spirulina-mediated reduction of AgNO₃, functionalized with glucose, and conjugated to lapatinib (Ag@Glu-Lapatinib NP), then characterized by FTIR, XRD, zeta potential, SEM, and TEM. SKBR3 cells were treated with Ag@Glu-Lapatinib NP, Ag NP, or lapatinib and evaluated by MTT, Annexin V/PI apoptosis assay, and RT-qPCR for candidate genes.
Results:
Transcriptomic analysis indicated that lapatinib suppresses proliferation-associated genes and enriches apoptosis-related pathways. In TCGA, ECE2 and CDCA5 were overexpressed and associated with poorer outcomes, whereas PDK4 and ALDH1A1 were reduced and linked to favorable prognosis. Ag@Glu-Lapatinib NP formation was confirmed, and the nanoformulation showed higher potency (IC₅₀ = 62 μg/mL at 24 h; 31 μg/mL at 48 h) than free lapatinib (250 μg/mL) or Ag NP (125 μg/mL), with markedly increased apoptosis. RT-qPCR verified significant modulation of ECE2, CDCA5, PDK4, and ALDH1A1 after Ag@Glu-Lapatinib NP treatment.
Conclusion:
Conjugating lapatinib to glucose-functionalized silver nanoparticles enhances its activity in HER2-positive BC cells and modulates survival-associated genes. This nano-therapeutic strategy may strengthen the therapeutic potential of lapatinib in breast cancer.
